Evolution of antimicrobials resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006;Évolution de la résistance aux antibiotiques de Pseudomonas aeruginosa dans un centre hospitalier universitaire entre 2002 et 2006

Pathologie Biologie

Volumn 58, Issue 1, 2010, Pages 1-6

  Minchella, A ^a   Molinari, L ^a   Alonso, S ^a   Bouziges, N ^a   Sotto, A ^a   Lavigne, J P ^a  

^a DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Antibiotic; Nosocomial strains; Pseudomonas aeruginosa; Resistance; Trend

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; FRANCE; HOSPITAL INFECTION; HUMAN; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STRAIN DIFFERENCE; UNIVERSITY HOSPITAL; CROSS INFECTION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; STATISTICS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 77349119830     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.08.002     Document Type: Article

References (32)

1. Pier G., Ramphal R. Pseudomonas aeruginosa. Principles and practice of infectious diseases. 2005, 2587-2615. Elsevier Churchill Livingstone, Philadelphia, PA. G. Mandell, J. Bennett, R. Dolin (Eds.).
2. Navon-Venezia S., Ben-Ami R., Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005, 18:306-313.
3. Oliver A., Cantón R., Campo P., Baquero F., Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1254.
4. Hogardt M., Hoboth C., Schmoldt S., Henke C., Bader L., Heesemann J. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 2007, 195:70-80.
5. Consulté le 29/07/2009. http://www.invs.sante.fr/publications/2009/enquete_prevalence_infections_nosocomiales/index.html.
6. Srinivasan A., Wolfenden L.L., Song X., Perl T.M., Haponik E.F. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003, 348:221-227.
7. Iversen B.G., Jacobsen T., Eriksen H.M., Bukholm G., Melby K.K., Nygård K., et al. An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs. Clin Infect Dis 2007, 44:794-801.
8. Mesaros N., Nordmann P., Plésiat P., Roussel-Delvallez M., Van Eldere J., Glupczynski Y., et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007, 13:560-578.
9. Vettoretti L., Floret N., Hocquet D., Dehecq B., Plésiat P., Talon D., et al. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol Infect Dis 2009, [Epub ahead of print].
10. Consulté le 29/07/09. http://www.sfm.asso.fr/.
11. Consulté le 29/07/09. http://cclin-sudest.chu-lyon.fr/prevention/guides/BMR_Personnel_06.pdf.
12. Consulté le 29/07/09. http://www.rivm.nl/earss/.
13. Bert F., Lambert-Zechovsky N. Résistance aux antibiotiques et problèmes thérapeutiques posés par Pseudomonas aeruginosa. Presse Med 1999, 28:451-458.
14. Carmeli Y., Troillet N., Karchmer A.W., Samore M.H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999, 159:1127-1132.
15. Harris A.D., Perencevich E., Roghmann M.C., Morris G., Kaye K., Johnson J. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002, 46:854-858.
16. Harris A.D., Smith D., Johnson J.A., Bradham D.D., Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002, 34:340-345.
17. Defez C., Fabbro-Peray P., Bouziges N., Gouby A., Mahamat A., Daurès J.P., et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004, 57:209-216.
18. Crespo M.P., Woodford N., Sinclair A., Kaufmann M.E., Turton J., Glover J., et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004, 42:5094-5101.
19. Tsukayama D.T., van Loon H.J., Cartwright C., Chmielewski B., Fluit A.C., van der Werken C., et al. The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial. Int J Antimicrob Agents 2004, 24:339-345.
20. Valles J., Mariscal D., Cortes P., Coll P., Villagrá A., Díaz E., et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med 2004, 30:1768-1775.
21. Consulté le 29/07/09. http://www.onerba.org/.
22. Souli M., Galani I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13:19045.
23. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
24. Consulté le 29/07/09. http://www.invs.sante.fr/surveillance/resistance/agents_pathogenes/fiche_pseudomonas_aeruginosa.pdf.
25. Consulté le 29/07/09. http://www.invs.sante.fr/publications/2009/enquete_prevalence_infections_nosocomiales/index.html.
26. Karlowsky J.A., Jones M.E., Thornsberry C., Evangelista A.T., Yee Y.C., Sahm D.F. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005, 40:S89-S98.
27. Falagas M.E., Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006, 64:7-15.
28. Consulté le 29/07/09. http://www.cclinparisnord.org/BACTERIEMIE/BACTERIEMIE.html.
29. McGowan J.E. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 2006, 34:S29-37.
30. Andrade S.S., Jones R.N., Gales A.C., Sader H.S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother 2003, 52:140-141.
31. Cavallo J.D., Hocquet D., Plesiat P., Fabre R., Roussel-Delvallez M. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J Antimicrob Chemother 2007, 59:1021-1024.
32. Rossolini G.M., Mantengoli E., Docquier J.D., Musmanno R.A., Coratza G. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiol 2007, 30:332-339.